Date of Award
8-23-2024
Degree Type
Thesis
Degree Name
Master of Science (MS)
Department
Biomedical and Chemical Engineering
Advisor(s)
Zhen Ma
Keywords
biomaterial;cardiac organoids;embryotoxicity;human induced pluripotent stem cell;in vitro model
Abstract
Medication use during pregnancy presents complex considerations due to its potential for causing congenital malformations and its implications for maternal and fetal health. With approximately 90% of pregnant women consuming at least one pharmaceutical agent, there is a critical need for comprehensive developmental toxicity screening, particularly for cancer treatments during pregnancy. Pluripotent stem cell (PSC) models, specifically iPSC-derived organoids, offer promising approaches for assessing drug toxicity and efficacy during pregnancy. This study introduces an embryotoxicity screening platform using biomaterial-engineered 3D cardiac organoids created through micropatterning techniques. The platform aims to characterize the response of six pharmaceutical agents across pregnancy risk categories, focusing on four chemotherapeutic compounds, based on the measurements of cardiac physiology and tissue morphology. The engineered cardiac organoids serve as a model for characterizing embryonic cardiac development and physiology, holding the potential to enhance diagnostic capabilities for chemotherapy-induced cardiotoxicity. This well-defined 3D structure is proposed as a pre-validation model for early-stage cardiotoxicity assessment, potentially contributing to an updated pregnancy risk classification system.
Access
Open Access
Recommended Citation
Chai, Meng, "Embryotoxicity of Chemotherapeutic Agents Tested Using Engineered Cardiac Organoids" (2024). Theses - ALL. 897.
https://surface.syr.edu/thesis/897
